Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.88M$1.88Mderived−88.7% vs Q4 2019 Net Income-$14.40M-$14.40MderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$12,411,000N/M Operating Cash Flowderived-$13,417,000N/M Free Cash Flowderived-$13,995,000N/M Margins · derivedOperating margin-661.2%−653.2 pt vs Q4 2019
Net margin-767.2%−762.6 pt vs Q4 2019
ended Dec 31, 2020 · filed Mar 31, 2021 · 90 d after period end